Medical/Pharmaceuticals News & Press Release Distribution

Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable

SHANGHAI, May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical Device Regulation (EU MDR) certification on May 18, 2026, under the registered name "Calcium Hydrox...

2026-05-28 15:55 4535

Scientific forum in Singapore explores advanced PET/CT imaging

SINGAPORE, May 28, 2026 /PRNewswire/ -- Singapore General Hospital (SGH), a leading academic medical centre in Singapore, on May 21 hosted "Advancing Precision Imaging with Next Generation PET/CT," a scientific forum that brought together experts in molecular imaging, nuclear medicine, radiology,...

2026-05-28 14:16 5408

Scientific forum in Singapore explores advanced PET/CT imaging

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for th...

2026-05-28 14:06 7511

Dymax Expands HLC Adhesive Portfolio with New Low Viscosity Medical Product

--New Adhesive Enables Reliable Bonding in Both Light and Shadowed Areas SINGAPORE, May 28, 2026 /PRNewswire/ -- Dymax, a global manufacturer of light-curing materials and equipment, today announced the release ofHLC-M-1004

2026-05-28 11:45 4479

Dymax Expands HLC Adhesive Portfolio with New Low Viscosity Medical Product

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...

2026-05-28 11:10 3787

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based thera...

2026-05-28 10:43 4797

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...

2026-05-28 10:37 4866

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-05-28 08:00 5052

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test

SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions , a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has grantedBreakthrough Device Design...

2026-05-28 06:00 5187

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Highlights: * Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements * Increase in sample size driven by enrolment rate exceeding original expectations ...

2026-05-27 22:41 7573

Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help

Weekly updates from the National Comprehensive Cancer Network share every time a change is made to evidence-based, expert consensus-driven guidelines for cancer prevention, screening, treatment, and supportive care. PLYMOUTH MEETING, Pa., May 27, 2026 /PRNewswire/ -- The National Comprehensive C...

2026-05-27 21:47 4594

Metabolon Expands Global Access to Metabolomics with the Metabolon Verus™ Metabolomics Profiling Kit

Democratizing metabolomics for researchers worldwide, the new kit brings Metabolon's analytically rigorous, scalable metabolomics into workflows designed for integrated biological insights MORRISVILLE, N.C., May 27, 2026 /PRNewswire/ -- Metabolon

2026-05-27 20:45 4186

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, Associate Director of Business Development...

2026-05-27 20:00 5330

From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, the roundtable featured Dr. Bing Xia, Vice...

2026-05-27 20:00 5766

Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV

- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII‑179 treatment achieved the most robust fun...

2026-05-27 19:00 5794

Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) h...

2026-05-27 18:40 6103

Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List

HONG KONG, May 27, 2026 /PRNewswire/ -- On 27 May 2026, Fortune China magazine released its 2026 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highlights...

2026-05-27 17:43 7060

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facil...

2026-05-27 17:14 7824

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

* DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development and regulatory approvals, including FDA IDE and PMA pathways * Full-scale entry into North America, the world's largest bone graft substi...

2026-05-27 14:00 5704

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs * CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China...

2026-05-27 13:00 5062